Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin"

Sci Transl Med. 2017 May 24;9(391):eaal2439. doi: 10.1126/scitranslmed.aal2439.

Stefan Winter¹, Pascale Fisel¹, Florian Büttner¹, Anne T Nies¹, Arnulf Stenzl^{2

3}, Jens Bedke^{2

3}, Matthias Schwab^{4

2

5

6}, Elke Schaeffeler¹

¹ Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr.112, 70376 Stuttgart, Germany.
² German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
³ Department of Urology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany.
⁴ Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr.112, 70376 Stuttgart, Germany. matthias.schwab@ikp-stuttgart.de.
⁵ Department of Clinical Pharmacology, University Hospital Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.
⁶ Department of Pharmacy and Biochemistry, University of Tuebingen, 72076 Tuebingen, Germany.

No abstract available

Publication types